Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer - Scorecard - MDSpire

Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer

  • By

  • Xianwei Yang

  • Xiaoling Liu

  • Shenghong Wan

  • Yilin Luo

  • Mengjun Shen

  • Xin Liao

  • July 14, 2026

Share

Clinical Scorecard: Creation and assessment of a multimodal radiomics nomogram for forecasting HER2 expression in invasive breast cancer patients

At a Glance

CategoryDetail
ConditionInvasive breast cancer
Key MechanismsHER2 expression status prediction using multimodal imaging and clinical features
Target PopulationPatients with pathologically confirmed invasive breast cancer
Care SettingPreoperative evaluation

Key Highlights

  • Developed a nomogram integrating DCE-MRI and mammography for HER2 status prediction
  • Achieved AUC values of 0.742 and 0.823 for HER2-positive vs. HER2-zero and HER2-positive vs. HER2-low respectively
  • Single DCE-MRI model showed optimal performance for HER2-low vs. HER2-zero with AUC of 0.831
  • Study included 204 patients with complete preoperative imaging data
  • Non-invasive approach aims to improve HER2 expression assessment

Guideline-Based Recommendations

Diagnosis

  • HER2 status determined via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)

Management

  • Utilize multimodal radiomics for non-invasive HER2 expression status evaluation

Monitoring & Follow-up

  • Monitor HER2 expression status for treatment decision-making

Risks

  • Invasive methods may not capture intratumoral heterogeneity

Patient & Prescribing Data

Female patients with invasive breast cancer

Non-invasive imaging techniques can aid in personalized treatment planning

Clinical Best Practices

  • Incorporate multimodal imaging features in preoperative assessments
  • Utilize clinical-radiomics nomograms for improved diagnostic accuracy

Related Resources & Content

    Original Source(s)

    Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer

    • by Xianwei Yang, Xiaoling Liu, Shenghong Wan, Yilin Luo, Mengjun Shen, Xin Liao

    • July 14, 2026

    Related Content

    Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

    Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

    Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

    • by

    • July 7, 2026

    • 8 min
    Metastatic malignant melanoma presenting as bilateral acute mastitis in a lactating woman: a case report and literature review